Co-Founder/CEO
Bolden Therapeutics
Bolden Therapeutics is developing first-in-class antisense oligonucleotides to enhance neurogenesis, targeting a specific molecular pathway to promote the formation of new neurons in the adult brain. This approach aims to address cognitive dysfunction associated with neurodegenerative diseases such as Alzheimer's and ischemic stroke.
- Biotechnology
Updated 23 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Features
- Bolden Therapeutics is developing first-in-class antisense oligonucleotides to enhance neurogenesis, targeting a specific molecular pathway to promote the formation of new neurons in the adult brain. This approach aims to address cognitive dysfunction associated with neurodegenerative diseases such as Alzheimer's and ischemic stroke.